Navigation Links
Warts vaccine -- 1 of many in pipeline

A clinical trial treating the papillomaviruses responsible for genital warts was on target at the halfway mark, according to Australian of the Year 2006 Professor Ian Frazer and trial manager, sexual health specialist Dr David Jardine

More than 200 patients in China and Australia have taken part in the trial so far run from the Princess Alexandra (PA) Hospital.

"The new treatment has so far proven safe, and we want to know if it improves the outcome after conventional therapy, which all patients also receive," Dr Jardine said.

Trial researchers aim to use a tweaked version of Professor Frazer’s cervical cancer vaccine to treat genital warts.

Professor Frazer said this vaccine could be one of the first made locally at the biopharmaceutical production centre, which received $100 million in last night’s Federal Budget.

The centre, called the Translational Research Institute, is planned to be a one-stop shop at the PA Hospital for medical research and health care, catering for medical discoveries, clinical trials and drug manufacture.

"Conducting trials in Australia gives Australians the chance to help develop new treatments," Professor Frazer said.

"Should the product under trial be effective, it also gives them the chance to be amongst the first to benefit."

A vaccine would complement both the pap smear program and currently available vaccines to prevent infections.

Genital warts are transmitted by skin contact and the 2003 Australian Study of Sex and Relationships of 20,000 adults revealed four percent of people had had visible genital warts.

Dr Jardine said men and women with genital warts who would like to take part in the trial could call 3240 5881 to learn more. All calls are handled in confidence.
'"/>

Source:Research Australia


Page: 1

Related biology news :

1. Research advances quest for HIV-1 vaccine
2. A much-needed shot in the arm for HIV vaccine development
3. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
4. Gene vaccine for Alzheimers disease shows promising results
5. Influenza vaccine uses insect cells to speed development
6. Norovirus, AIDS vaccine and Hepatitis Virus
7. HIV vaccine trial breaks ground for future research
8. Live vaccines more effective against horse herpes virus
9. NIAID begins clinical trial of West Nile virus vaccine
10. Designing vaccines by computer
11. Wake Forest scientists find new combination vaccine effective against plague
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, into ... for over 35 years, is proud to add Target to its list of ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology: